Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: Twelve-year results and retrospective subgroup analysis

Breast Cancer Research and Treatment

Volumn 108, Issue 2, 2008, Pages 259-264

  Amadori, Dino ^a   Nanni, Oriana ^a   Volpi, Annalisa ^a   Casadei Giunchi, Donata ^b   Marangolo, Maurizio ^c   Livi, Lorenzo ^d   Ravaioli, Alberto ^e   Rossi, Andrea Paolo ^f   Gambi, Angelo ^g   Luzi Fedeli, Stefano ^h   Perroni, Davide ⁱ   Scarpi, Emanuela ^a   Becciolini, Aldo ^d   Silvestrini, Rosella ^a  

^a DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^b MORGAGNI PIERANTONI HOSPITAL   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

^d CAREGGI UNIVERSITY HOSPITAL   (Italy)

^e INFERMI HOSPITAL   (Italy)

^f BUFALINI HOSPITAL   (Italy)

^g Degli Infermi Hospital   (Italy)

^h SAN SALVATORE HOSPITAL   (Italy)

ⁱ S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Adjuvant CMF; High risk node negative breast cancer; Randomized study; Tumor Proliferative activity

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE; THYMIDINE;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; STATISTICAL ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; ITALY; KAPLAN-MEIERS ESTIMATE; LYMPH NODES; METHOTREXATE; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME;

EID: 39749110535     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9593-9     Document Type: Article

References (19)

1. Silvestrini R, Luisi A, Daidone MG et al (1998) Effect of menstrual phase on cell proliferative rate of breast cancer. Breast Cancer Res Treat 48:93-94
2. Tubiana M, Pejovic MH, Koscielny S et al (1989) Growth rate, kinetics of tumor cell proliferation and long-term outcome in human breast cancer. Int J Cancer 44:17-22
3. Meyer JS, Province M (1988) Proliferative index of breast carcinoma by thymidine labeling: prognostic power independent of stage, estrogen and progesterone receptors. Breast Cancer Res Treat 12:191-204
4. Volpi A, De Paola F, Nanni O et al (2000) Prognostic significance of biologic markers in node-negative breast cancer patients: a prospective study. Breast Cancer Res Treat 63:181-192
5. Volpi A, Nanni O, De Paola F et al (2003) HER-2 expression and cell proliferation: prognostic markers in patients with node-negative breast cancer. J Clin Oncol 21:2708-2712
6. Amadori D, Nanni O, Marangolo M et al (2000) Disease-free survival advantage of adjuvant cyclophosphamide, methotrexate, and fluorouracil in patients with node-negative, rapidly proliferating breast cancer: a randomized multicenter study. J Clin Oncol 18:3125-3134
7. Paradiso A, Schittulli F, Cellamare G et al (2001) Randomized clinical trial of adjuvant fluorouracil, epirubicin, and cyclophosphamide chemotherapy for patients with fast-proliferating, node-negative breast cancer. J Clin Oncol 19:3929-3937
8. Colozza M, Azambuja E, Cardoso F et al (2005) Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann Oncol 16:1723-1739
9. Silvestrini R, Benini E, Daidone MG et al (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85:965-970
10. Piffanelli A, Pelizzola D, Giovannini G et al (1989) Characterization of laboratory working standard for quality control of immunometric and radiometric estrogen receptor assays. Clinical evaluation on breast cancer biopsies. Italian Committee for Hormone Receptor Assays Standardization. Tumori 75:550-556
11. Silvestrini R (1991) Feasibility and reproducibility of the [3H]-thymidine labelling index in breast cancer. The SICCAB Group for Quality Control of Cell Kinetic Determination. Cell Prolif 24:437-445
12. Paradiso A, Volpe S, Iacobacci A et al (2002) Quality control for biomarker determination in oncology: the experience of the Italian Network for Quality Assessment of Tumor Biomarkers (INQAT). Int J Biol Markers 17:201-214
13. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365:1687-1717
14. Henderson IC, Berry DA, Demetri GD et al (2003) Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983
15. Martin M, Pienkowski T, Mackey J et al (2005) Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 352:2302-2313
16. Amadori D, Volpi A, Maltoni R et al (1997) Cell proliferation as a predictor of response to chemotherapy in metastatic breast cancer: a prospective study. Breast Cancer Res Treat 43:7-14
17. Gardin G, Alama A, Rosso R et al (1994) Relationship of variations in tumor cell kinetics induced by primary chemotherapy to tumor regression and prognosis in locally advanced breast cancer. Breast Cancer Res Treat 32:311-318
18. Silvestrini R, Luisi A, Zambetti M et al (2000) Cell proliferation and outcome following doxorubicin plus CMF regimens in node-positive breast cancer. Int J Cancer 87:405-411
19. Bonadonna G, Valagussa P (1981) Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 304:10-15